Comparative Pharmacology
Head-to-head clinical analysis: CEFOBID versus TAZICEF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFOBID versus TAZICEF.
CEFOBID vs TAZICEF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefoperazone is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting peptidoglycan cross-linking and causing cell lysis.
Ceftazidime is a third-generation cephalosporin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP-3, leading to cell lysis and death.
2-4 g/day IV/IM divided q12h; severe infections: 6-12 g/day IV divided q8-12h
2 g intravenously every 8 hours for serious infections; 1 g intravenously every 8 hours for uncomplicated infections.
None Documented
None Documented
2 hours (prolonged in hepatic impairment and neonates).
2 hours (prolonged to 4-12 hours in renal impairment; anuria: 20-30 hours).
Primarily renal (80-90% unchanged in urine) and biliary (10-20%).
Primarily renal (80-90% unchanged via glomerular filtration and tubular secretion); biliary/fecal <10%.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic